Disc Medicine, Inc. - 8-K Filing
Disc Medicine reports Q3 2026 results with $682.8 million in cash and positive Phase 3 APOLLO trial data for bitopertin. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)